Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Perioperative MSI/dMMR Tumors
2020-004957-62Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in microsatellite instability-high cancer, mismatch repair deficient solid tumor and gastric cancer (GC), sponsored by Centre Léon Bérard. Primary endpoint: Pathologic complete response rate. Started Mar 2021; status: active.
02
Drugs
03
Conditions
microsatellite instability-high cancermismatch repair deficient solid tumorgastric cancer (GC)
Beyond the preview
Go deeper on 2020-004957-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004957-62.